Literature DB >> 30675371

Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations.

Mehdi Layeghifard1, Hannah Li2, Pauline W Wang1,3, Sylva L Donaldson3, Bryan Coburn4, Shawn T Clark5, Julio Diaz Caballero1, Yu Zhang5, D Elizabeth Tullis6, Yvonne C W Yau7,8, Valerie Waters9, David M Hwang4,5,10, David S Guttman1,3.   

Abstract

Over 90% of cystic fibrosis (CF) patients die due to chronic lung infections leading to respiratory failure. The decline in CF lung function is greatly accelerated by intermittent and progressively severe acute pulmonary exacerbations (PEs). Despite their clinical impact, surprisingly few microbiological signals associated with PEs have been identified. Here we introduce an unsupervised, systems-oriented approach to identify key members of the microbiota. We used two CF sputum microbiome data sets that were longitudinally collected through periods spanning baseline health and PEs. Key taxa were defined based on three strategies: overall relative abundance, prevalence, and co-occurrence network interconnectedness. We measured the association between changes in the abundance of the key taxa and changes in patient clinical status over time via change-point detection, and found that taxa with the highest level of network interconnectedness tracked changes in patient health significantly better than taxa with the highest abundance or prevalence. We also cross-sectionally stratified all samples into the clinical states and identified key taxa associated with each state. We found that network interconnectedness most strongly delineated the taxa among clinical states, and that anaerobic bacteria were over-represented during PEs. Many of these anaerobes are oropharyngeal bacteria that have been previously isolated from the respiratory tract, and/or have been studied for their role in CF. The observed shift in community structure, and the association of anaerobic taxa and PEs lends further support to the growing consensus that anoxic conditions and the subsequent growth of anaerobic microbes are important predictors of PEs.

Entities:  

Mesh:

Year:  2019        PMID: 30675371      PMCID: PMC6341074          DOI: 10.1038/s41522-018-0077-y

Source DB:  PubMed          Journal:  NPJ Biofilms Microbiomes        ISSN: 2055-5008            Impact factor:   7.290


  54 in total

1.  Defining a pulmonary exacerbation in cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; J Williams-Warren; M Pepe; A Smith; A B Montgomery; B Ramsey
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

2.  Anaerobic bacterial infection in patients with cystic fibrosis.

Authors:  Andrew Tai; Sarath Ranganath
Journal:  Am J Respir Crit Care Med       Date:  2008-11-01       Impact factor: 21.405

3.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 4.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

5.  Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication.

Authors:  Kangmin Duan; Carol Dammel; Jeffrey Stein; Harvey Rabin; Michael G Surette
Journal:  Mol Microbiol       Date:  2003-12       Impact factor: 3.501

6.  Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa.

Authors:  Shawn D Aaron; Karam Ramotar; Wendy Ferris; Katherine Vandemheen; Raphael Saginur; Elizabeth Tullis; David Haase; Dan Kottachchi; Melissa St Denis; Francis Chan
Journal:  Am J Respir Crit Care Med       Date:  2003-12-11       Impact factor: 21.405

7.  Antimicrobial susceptibilities and clinical sources of Dialister species.

Authors:  F Morio; H Jean-Pierre; L Dubreuil; E Jumas-Bilak; L Calvet; G Mercier; R Devine; H Marchandin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

8.  Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.

Authors:  Michael M Tunney; Tyler R Field; Thomas F Moriarty; Sheila Patrick; Gerd Doering; Marianne S Muhlebach; Matthew C Wolfgang; Richard Boucher; Deirdre F Gilpin; Andrew McDowell; J Stuart Elborn
Journal:  Am J Respir Crit Care Med       Date:  2008-02-08       Impact factor: 21.405

9.  Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.

Authors:  D Worlitzsch; C Rintelen; K Böhm; B Wollschläger; N Merkel; M Borneff-Lipp; G Döring
Journal:  Clin Microbiol Infect       Date:  2009-01-22       Impact factor: 8.067

Review 10.  Species divergence and the measurement of microbial diversity.

Authors:  Catherine A Lozupone; Rob Knight
Journal:  FEMS Microbiol Rev       Date:  2008-04-22       Impact factor: 16.408

View more
  21 in total

1.  NetCoMi: network construction and comparison for microbiome data in R.

Authors:  Stefanie Peschel; Christian L Müller; Erika von Mutius; Anne-Laure Boulesteix; Martin Depner
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

Review 2.  Perspectives in lung microbiome research.

Authors:  Imran Sulaiman; Sheeja Schuster; Leopoldo N Segal
Journal:  Curr Opin Microbiol       Date:  2020-07-02       Impact factor: 7.934

3.  Analysis of airway microbiota in adults from a Brazilian cystic fibrosis center.

Authors:  Cassiana Costa Ferreira Leite; Flavia Alvim Dutra de Freitas; Mônica de Cássia Firmida; Robson Souza Leão; Rodolpho Mattos Albano; Elizabeth Andrade Marques
Journal:  Braz J Microbiol       Date:  2020-09-17       Impact factor: 2.476

4.  Methods for Extraction and Detection of Pf Bacteriophage DNA from the Sputum of Patients with Cystic Fibrosis.

Authors:  Elizabeth B Burgener; Patrick R Secor; Michael C Tracy; Johanna M Sweere; Elisabeth M Bik; Carlos E Milla; Paul L Bollyky
Journal:  Phage (New Rochelle)       Date:  2020-06-16

5.  Citizen-science based study of the oral microbiome in Cystic fibrosis and matched controls reveals major differences in diversity and abundance of bacterial and fungal species.

Authors:  Jesse R Willis; Ester Saus; Susana Iraola-Guzmán; Elena Cabello-Yeves; Ewa Ksiezopolska; Luca Cozzuto; Luis A Bejarano; Nuria Andreu-Somavilla; Miriam Alloza-Trabado; Andrea Blanco; Anna Puig-Sola; Elisabetta Broglio; Carlo Carolis; Julia Ponomarenko; Jochen Hecht; Toni Gabaldón
Journal:  J Oral Microbiol       Date:  2021-05-17       Impact factor: 5.474

6.  Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.

Authors:  Lindsay J Caverly; Junnan Lu; Lisa A Carmody; Linda M Kalikin; Kerby Shedden; Kristopher Opron; Michelle Azar; Shannon Cahalan; Bridget Foster; Donald R VanDevanter; Richard H Simon; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2019-12

7.  High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy.

Authors:  Ruma Raghuvanshi; Karla Vasco; Yoshiki Vázquez-Baeza; Lingjing Jiang; James T Morton; Danxun Li; Antonio Gonzalez; Lindsay DeRight Goldasich; Gregory Humphrey; Gail Ackermann; Austin D Swafford; Douglas Conrad; Rob Knight; Pieter C Dorrestein; Robert A Quinn
Journal:  mSystems       Date:  2020-06-23       Impact factor: 6.496

8.  Metabolic Modeling of Cystic Fibrosis Airway Communities Predicts Mechanisms of Pathogen Dominance.

Authors:  Michael A Henson; Giulia Orazi; Poonam Phalak; George A O'Toole
Journal:  mSystems       Date:  2019-04-23       Impact factor: 6.496

9.  Key Bacteria in the Gut Microbiota Network for the Transition between Sedentary and Active Lifestyle.

Authors:  Nazareth Castellanos; Gustavo G Diez; Carmen Antúnez-Almagro; Carlo Bressa; María Bailén; Rocío González-Soltero; Margarita Pérez; Mar Larrosa
Journal:  Microorganisms       Date:  2020-05-24

10.  Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.

Authors:  Lauren M Castner; Madsen Zimbric; Shannon Cahalan; Corey Powell; Lindsay J Caverly
Journal:  J Cyst Fibros       Date:  2021-02-19       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.